Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update

Autor: Tom Boyles, Rebecca H. Berhanu, Neliswa Gogela, Hannah Gunter, Tamsin Lovelock, Ndiviwe Mphothulo, Arifa Parker, Helena Rabie, Lauren Richards, Phumla Sinxadi, Camilla Wattrus, Mahomed-Yunus Moosa

Publikováno v: Southern African Journal of HIV Medicine, Vol 25, Iss 1, Pp e1-e7 (2024)

No abstract available.

Externí odkaz: https://doaj.org/article/cc3defcc458b4611af33f838736a4cb5

Hepatitis C prevalence in HIVinfected heterosexual men and men who have sex with men

Autor: Neliswa Gogela, Kevin Rebe, C W Spearman, Mark W. Sonderup, Tawanda Chivese

Publikováno v: South African Medical Journal, Vol 108, Iss 7, Pp 568-572 (2018)
South African Medical Journal; Vol 108, No 7 (2018)
SAMJ: South African Medical Journal, Volume: 108, Issue: 7, Pages: 568-572, Published: JUL 2018

Background. Globally 1% of individuals are infected with hepatitis C virus (HCV). In South Africa (SA) the prevalence ranges between 0.3% and 1%, with few prospective screening data available. Similarly, local data on transmission modes of HCV are li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88d802aaee8a5715a72a78e64f6beef9
http://www.samj.org.za/index.php/samj/article/download/12332/8521

Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets

Autor: Philip Lam, Reidwaan Ally, Chris Kassianides, John Rwegasha, Olufunmilayo A. Lesi, Emmanuel Musabeyezu, Christian Tzeuton, Mark W. Sonderup, Michael C. Kew, Neliswa Gogela, Geoffrey Dusheiko, Yaw Asante Awuku, Lina Cunha, Betty Musau, Abate B. Shewaye, Barbara Scholz, O S Ojo, Papa Saliou Mbaye, C Wendy Spearman, Marie Jeanne Lohouès-Kouacou, Betty S. Apica, Mary Afihene

Publikováno v: The Lancet Gastroenterology & Hepatology. 2:900-909

The WHO global health sector strategy on viral hepatitis, created in May, 2016, aims to achieve a 90% reduction in new cases of chronic hepatitis B and C and a 65% reduction in mortality due to hepatitis B and C by 2030. Hepatitis B virus (HBV) is en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aac53524c08f578daedc126d7246b91
https://doi.org/10.1016/s2468-1253(17)30295-9

Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa

Autor: Diana Hardie, C W Spearman, Mark W. Sonderup, Heidi Smuts, Stephen N.J. Korsman, Neliswa Gogela, R Nordien

Publikováno v: South African Medical Journal. 110:112

Background. An estimated 600 000 South Africans are chronically infected with hepatitis C virus (HCV). To date, accurate prevalence data are lacking, but emerging data suggest a significant burden in key populations. Historically, pegylated interfero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::256def8aee305a4f10e8e9d4966be518
https://doi.org/10.7196/samj.2020.v110i2.14195

Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment

Autor: Neliswa Gogela, Arthur Y. Kim, Raymond T. Chung, Tokunbo Ajayi, Sara Lammert, Justin Chan, Zachary P. Fricker, Hui Zheng, Gregory K. Robbins

Publikováno v: Digestive diseases and sciences. 63(2)

Liver fibrosis stage determines risk of morbidity and mortality from chronic hepatitis C virus (HCV) infection. Prior data have shown long-term reversal of liver fibrosis, measured by vibration-controlled transient elastography (VCTE), in patients su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9df638f69706c7d49d0bed565a92c39a
https://pubmed.ncbi.nlm.nih.gov/28887750